{"page_content": " 42\nThroughout this report we have shared Alkermes\u2019 2020 ESG \nperformance metrics and ESG initiatives and activities and \nsome early insights into our 2021 ESG activities. As part of \nour efforts to advance our corporate responsibility strategy, \nwe plan to undertake a variety of initiatives in the coming \nyears, including:\n\u2022 Create a sustainability framework containing definitions,  \nmetrics, standards and tracking mechanisms to measure  \nthe environmental impact of new projects;\n\u2022 Establish baseline data and concrete sustainability goals  \nto hold ourselves accountable for continuous and  \nsustainable growth;\n\u2022 Align our goals and progress with international \nsustainability frameworks;\n\u2022 Develop a more thorough and strategic corporate  \nresponsibility strategy encompassing ESG policies, goals  \nand actions.\nWe look forward to sharing our future progress in reports  \nto come.\nNote Regarding Forward-\nLooking Statements\nCertain statements set forth in this report constitute \u201cforward-\nlooking statements\u201d within the meaning of the Private \nSecurities Litigation Reform Act of 1995, as amended, \nincluding, but not limited to, statements concerning: the \npotential clinical, therapeutic and commercial value of the \nCompany\u2019s medicines and product candidates; the Company\u2019s \nESG policies, commitments and initiatives and the intended \nimpact of such initiatives on patients, their families and \ncommunities; the Company\u2019s environmental footprint; the \npotential impacts of the Company\u2019s efforts to expand access \nto medicines, its policy and advocacy activities and patient \nengagement and grant programs in helping to address broad \npublic health issues, including among people living with \nserious mental illness, addiction and cancer; the Company\u2019s \nplans for continued and future ESG programs and activities, including diversity, inclusion and belonging initiatives, \nand ongoing development of the Company\u2019s corporate \nresponsibility strategy.\nThe Company cautions that forward-looking statements are \ninherently uncertain. Although the Company believes that \nsuch statements are based on reasonable assumptions within \nthe bounds of its knowledge of its business and operations, \nthe forward-looking statements are neither promises nor \nguarantees and they are necessarily subject to a high degree \nof uncertainty and risk. Actual performance and results \nmay differ materially from those expressed or implied in \nthe forward-looking statements due to various risks and \nuncertainties. These risks and uncertainties include those risks \ndescribed in the Alkermes plc Annual Report on Form 10-K \nfor the year ended Dec. 31, 2020 and in subsequent filings \nmade by the Company with the SEC, which are available on \nthe SEC\u2019s website at www.sec.gov. The information contained \nin this report is provided by the Company as of the date \nhereof, and, except as required by law, the Company disclaims \nany intention or responsibility for updating or revising any \nforward-looking information contained in this report.\nNote Regarding Trademarks\nARISTADA\u00ae and ARISTADA INITIO\u00ae are registered \ntrademarks of Alkermes Pharma Ireland Limited. ALKERMES\u00ae, \nthe ALKERMES design, ALKERMES INSPIRATION GRANTS\u00ae, \nALKERMES PATHWAYS RESEARCH AWARDS\u00ae and \nVIVITROL\u00ae are registered trademarks or service marks of \nAlkermes, Inc. The ALKERMES INSPIRATION GRANTS logo  \nis a service mark of Alkermes, Inc.\nSECTION 9 \nTHE FUTURE OF  \nCORPORATE  \nRESPONSIBILITY \nAT ALKERMES  \nALKERMES \u2022  CORPORATE RESPONSIBILITY REPORT \u2022 THE FUTURE OF CORPORATE RESPONSIBILITY AT ALKERMES", "metadata": {"source": "NASDAQ_ALKS_2021.pdf", "page": 41, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}